Cell Therapeutics Inc (CTIC.OQ)
|Market Cap (Mil.):||$225.93|
|Shares Outstanding (Mil.):||129.84|
BRIEF-Cell Therapeutics up 8.6 percent premarket; expects $67 million in cash milestone payments from Baxter through 2015
NEW YORK, Nov 18 - Cell Therapeutics Inc : * Up 8.6 percent to $2.03 in premarket; expects $67 million in cash milestone payments from Baxter through 2015
BRIEF-Cell Therapeutics expects to get $67 mln in cash milestone payments from Baxter through 2015 - SEC filing
Nov 18 - Cell Therapeutics Inc : * Expects could pay up to $96 million in development costs for persist-1 & 2
- Cell Therapeutics Inc's shares rose as much as 24 percent after Baxter International Inc threw its financial and marketing heft behind the smaller company's bone marrow disorder drug.
(Adds details, CEO comments from conference call, analyst comments; adds share movement)
Nov 15 - Baxter International Inc agreed to develop and market Cell Therapeutics Inc's bone marrow disorder drug for payments that could total up to $362 million, sending Cell Therapeutics' shares up more than 30 percent before the bell.
June 24 - Cell Therapeutics Inc said the U.S. Food and Drug Administration has placed a partial clinical hold on the company's experimental blood cancer drug after the death of a patient.
|Astellas Pharma Inc (4503.T)||¥6,110||+150.00|
|Eisai Co., Ltd (4523.T)||¥3,990||+25.00|
|Roche Holding Ltd. (ROG.VX)||CHF241.80||+5.20|
|Sanofi SA (SASY.PA)||€75.21||+1.88|
|Eli Lilly & Co. (LLY.N)||$49.97||-0.54|
|Bristol-Myers Squibb Co (BMY.N)||$53.77||+1.18|
|Bristol-Myers Squibb Co (BMYMP.PK)||$875.00||+1.96|
|Celgene Corporation (CELG.OQ)||$163.33||+0.85|
|Telik, Inc. (TELK.OQ)||$1.24||-0.06|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.
Provider: S&P Capital IQ Quantitative Report
Provider: Pechala's Reports
Cell Therapeutics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile